Evidence map›Paper›PMID 37008164›Full record

ArticleHemaSphere2023

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.

Miguel A Canales, Thomas A Buchholz, Jaisson A P Bortolini, Laura M Fogliatto, Takayuki Ishikawa, Koji Izutsu, Antonio Salar, Jeff P Sharman, Dirk Klingbiel, Sunny Pokala and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. [Chinese expert consensus on short duration infusion of obinutuzumab (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 6 countries.

Miguel A CanalesHospital Universitario La Paz, Madrid, Spain.
Thomas A BuchholzScripps MD Anderson Cancer Center, San Diego, CA, USA.
Jaisson A P BortoliniCentro de Pesquisas Oncologicas, Florianopolis, Brazil.
Laura M FogliattoHospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Takayuki IshikawaKobe City Medical Center, General Hospital, Hyogo, Japan.
Koji IzutsuNational Cancer Center Hospital, Tokyo, Japan.
Antonio SalarHospital del Mar, Barcelona, Spain.
Jeff P SharmanWillamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.
Dirk KlingbielF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sunny PokalaF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ekaterina VorozheikinaIQVIA Medical and Scientific Services, Moscow, Russia.
Peter TraskGenentech, Inc., South San Francisco, CA, USA.
Joana ParreiraF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Kai HübelUniklinik Köln, Department I of Internal Medicine, Cologne, Germany.
Roche (Switzerland) · CHCentro de Pesquisas Oncológicas · BRHospital de Clínicas de Porto Alegre · BRHospital Del Mar · ESHospital Universitario La Paz · ESKobe City Medical Center General Hospital · JPScripps MD Anderson Cancer Center · USTokyo National Hospital · JPUniversity Hospital Cologne · DEWillamette Valley Cancer Institute and Research Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37008164
PMCPMC10065834
OpenAlexW4361271330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.